Shaonan Xie

Shaonan Xie

Auto-generated profile, based on publicly available information

Shaonan Xie

Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Recent Patents on Anti-Cancer Drug Discovery
Verified
Journal Article
Closed access
PDF file
BZBosheng Zheng
Bosheng Zheng
WZWei Zhang
Wei Zhang
SXShaonan Xie
Shaonan Xie
YHYaqing Han
Yaqing Han
GLGuangjie Liu
Guangjie Liu
QLQingyi Liu
Qingyi Liu
Selinexor treats lung cancer, particularly non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). This review summarizes the prevalence and types of lung cancer and emphasizes the challenges associated with current treatments like resistance and limited effectiveness. Selinexor is a selective inhibitor of nuclear export (SINE) that has emerged as a potential therapy that targets the nuclear export of tumor suppressor proteins. The mechanisms of selinexor, its potential in combination therapies, and challenges like side effects and drug resistance are explained in this review. Key findings highlight the effectiveness of selinexor in preclinical studies, particularly against KRAS-mutant NSCLC and in combination with chemotherapy for SCLC. The review concludes with a discussion of future directions and underscores the potential of selinexor to improve the treatment strategies for lung cancer.

22 March 2021 in Research Square
Verified
Preprint
Open access
PDF file
SXShaonan Xie
Shaonan Xie
CWCheng Wang
Cheng Wang
SLShaoteng Li
Shaoteng Li
HDHuiyan Deng
Huiyan Deng
YHYaqing Han
Yaqing Han
QLQingyi Liu
Qingyi Liu
Background: Synchronous multiple ground-glass nodules (SMGGNs) in synchronous multiple lung cancers (SMLCs) are associated with specific imaging findings. It is difficult to distinguish whether multiple nodules are primary tumors or metastatic lesions in the lungs. The need for positron-emission tomography/computed tomography (PET/CT) and contrast-enhanced brain magnetic resonance imaging (MRI) for these patients remains unclear. This study investigated the necessity of these two imaging examinations for SMGGN patients by means of retrospective analysis. Methods: SMGGN patients who were diagnosed and treated in the Department of Thoracic Surgery in our hospital from October 2017 to May 2020 and underwent whole-body PET/CT and/or contrast-enhanced brain MRI examinations were enrolled in this study. We analyzed the imaging and clinical characteristics of these patients to evaluate SMGGN patients’ need to undergo whole-body PET/CT and brain MRI examination. Results: A total of 87 SMGGN patients (26 men and 61 women, with a median age of 58 years at onset) were enrolled. Fifty-one patients underwent whole-body PET/CT examinations and did not show signs of primary tumors in other organs, metastatic foci in other organs, or metastasis to surrounding lymph nodes. Eighty-seven patients underwent whole-brain MRI, which did not reveal brain metastases but did detect an old cerebral infarction in 23 patients and a new cerebral infarction in one patient. Eighty-seven patients underwent surgical treatment in which 219 nodules were removed. All nodules were diagnosed as adenocarcinoma or atypical adenomatous hyperplasia. No lymph node metastasis was noted. Conclusion: For SMGGN patients, it is not necessary to perform a whole-body PET/CT examination before surgery. Contrast-enhanced brain MRI can assess the patient’s cerebrovascular function before surgery and reduce the risk of perioperative cerebrovascular accidents. Thus, it is a necessary examination.